evipedia.ai
← Back

L-Tyrosine for Health & Longevity

Evidence Review created on 10/22/2026 using AI4L / Opus 5.5

Also known as: Tyrosine, L-Tyr, Tyr, 4-hydroxyphenylalanine, para-hydroxyphenylalanine

Motivation

L-Tyrosine is an amino acid found in protein-rich foods such as meat, fish, dairy, and soy, and the body can also make it from another amino acid. The brain uses it as raw material for dopamine and related chemical messengers involved in focus, motivation, and the response to stress, which is why it is sold as a supplement for mental performance.

Interest grew out of military research programs that asked whether extra tyrosine could protect thinking and mood during cold, thin air, sleep loss, and harsh training. The idea later spread to students, athletes, and people looking for a non-stimulant aid for demanding mental work, and newer genetic studies have asked how the body’s own tyrosine levels relate to long-term metabolic health and lifespan.

This review examines the human evidence on supplemental L-Tyrosine for thinking under pressure, mood, and healthy aging, alongside its side effects, interactions, dosing, and monitoring. Its purpose is to map how strong, how consistent, and how complete that evidence is for health-focused adults considering it.

Benefits - Risks - Protocol - Conclusion

Selected expert podcasts, commentary, and narrative reviews that give a high-level overview of L-Tyrosine and its main mechanism.

Note: Rhonda Patrick’s only tyrosine discussion (FoundMyFitness Q&A #52) is a members-only episode and is not openly accessible. No directly relevant content was found from Peter Attia (his site search returned no results and web search found only a guest’s passing remark) or from Chris Kresser (only brief mentions: a sentence in a general article on nootropics and a passing remark in a 2012 podcast Q&A about pairing morning tyrosine with evening 5-HTP (a serotonin precursor); neither discusses L-Tyrosine in enough depth to qualify).

Grokipedia

Tyrosine

Encyclopedic overview of tyrosine’s chemistry, biosynthesis, breakdown, roles as precursor to dopamine, thyroid hormones, and melanin, inherited metabolic disorders, and medical and supplemental uses.

Examine

L-Tyrosine

Evidence-graded summary drawing on 24 trials and one meta-analysis, with studied dose ranges, timing before stress, formulation notes, and a dedicated safety section.

ConsumerLab

L-Tyrosine: Health Effects and Safety

Reviews evidence for stress, phenylketonuria (inherited inability to process phenylalanine), depression, and attention deficit, plus safety notes on thyroid disease, certain antidepressants, levodopa (a Parkinson’s drug), and melanoma.

Systematic Reviews

Systematic reviews and meta-analyses of supplemental L-Tyrosine and of the body’s own blood tyrosine, identified through PubMed.

No systematic review or meta-analysis of adverse events from supplemental L-Tyrosine was found; the risk side is represented only by the observational meta-analysis of the body’s own blood tyrosine above.

Mechanism of Action

L-Tyrosine is the starting material for the catecholamines dopamine, noradrenaline, and adrenaline. Tyrosine hydroxylase (the rate-limiting enzyme that converts tyrosine to L-DOPA, dopamine’s immediate precursor) is not fully saturated at normal brain tyrosine levels, so extra supply can raise catecholamine synthesis, mainly in neurons that are firing rapidly, as during stress or heavy mental load (Fernstrom & Fernstrom, 2007). This depletion-repletion model predicts benefit only when demand outstrips supply (Jongkees et al., 2015).

  • Other products: Tyrosine is also built into the thyroid hormones thyroxine (T4) and triiodothyronine (T3) and into the skin pigment melanin.
  • Competing explanation: Dopamine’s effects follow an inverted U, so extra precursor can overshoot already-active systems, possibly explaining worse performance in some older adults (van de Rest et al., 2017) and high performers (Jongkees, 2020).
  • Absorption and half-life: In four adolescents, blood levels peaked about 2–3 hours after an oral dose and approached baseline by 8 hours (Hart et al., 2021); a formal elimination half-life for supplemental doses has not been reported.
  • Tissue distribution: It enters the brain via the large neutral amino acid transporter (LAT1, a carrier shared with leucine and tryptophan), so protein-rich meals compete (Fernstrom & Fernstrom, 2007).
  • Selectivity: It is an enzyme substrate with no direct receptor targets.
  • Metabolism: The liver breaks it down via tyrosine aminotransferase (TAT, the first enzyme of tyrosine breakdown) to fumarate and acetoacetate (energy-yielding compounds) (Matsumoto et al., 2026, a trial funded and run by the amino acid manufacturer Ajinomoto).

Historical Context & Evolution

Tyrosine was first isolated from the cheese protein casein by the German chemist Justus von Liebig in 1846; its name comes from the Greek word for cheese. For more than a century it was studied as an ordinary protein building block and, later, as the nutrient that becomes essential in phenylketonuria diets.

Its use for health optimization began in the 1970s, when Richard Wurtman’s group at the Massachusetts Institute of Technology showed that brain neurotransmitter synthesis responds to the supply of dietary precursors (summarized in a 2007 review by Fernstrom & Fernstrom). That idea prompted trials of tyrosine for depression; a placebo-controlled trial in 65 outpatients found that it raised a noradrenaline breakdown product without lifting mood (Gelenberg et al., 1990).

From 1989, US Army and Navy laboratories tested tyrosine against cold, low oxygen, and sleep loss, reporting fewer symptoms and preserved performance in volunteers most affected by the stressor (Banderet & Lieberman, 1989). In the 2010s, a Leiden group extended the work to unstressed but mentally demanding tasks (Colzato et al., 2013).

Opinion has since shifted on several fronts: exercise trials and a meta-analysis found no endurance benefit (Solon-Júnior et al., 2023), studies in older adults raised the possibility of dose-related harm (van de Rest et al., 2017), and genetic analyses began relating blood tyrosine to metabolic risk and lifespan (Jäger et al., 2020; Zhao et al., 2025). None of these settles the question; each adds evidence about a specific population or outcome.

Expected Benefits

High 🟩 🟩 🟩

Working memory and cognitive control under stress or heavy load ⚠️ Conflicted

Acute doses preserved working memory, attention, or vigilance during cold, low oxygen, sleep loss, or high task demand in trials from US Army (Banderet and Lieberman 1989; Mahoney 2007), US Navy (Shurtleff 1994; Neri 1995), and Leiden (Colzato 2013) groups. A rapid systematic review rated this support as weak (Attipoe et al., 2015). Two heat-stress trials found no benefit (Coull et al., 2016; Donnan et al., 2025), and under high cognitive load tyrosine worsened cognitive flexibility (Robson et al., 2020). Net: small, task-specific gains under stress, inconsistent across tasks.

Magnitude: On the hardest working-memory condition (2-back, recalling items two steps back), accuracy was 91.4% after tyrosine versus 86.5% after placebo (P = 0.02, a p-value giving the probability that a difference this large arises by chance; no confidence interval, CI, the range likely to contain the true effect, reported) (Colzato et al., 2013).

Medium 🟩 🟩

Core body temperature maintenance in older adults during cold

With age, the skin’s blood vessels constrict less in cold, so more body heat is lost. In a randomized double-blind crossover trial in 9 older and 9 young adults, 150 mg/kg before 90 minutes of whole-body cooling strengthened this constriction and preserved core temperature in older but not young participants (Lang et al., 2020). An earlier trial from the same Lang group showed the vessel response (Lang & Smaller, 2017). Evidence comes from one research group and brief laboratory exposures.

Magnitude: In older adults, core temperature changed by −0.07 °C with tyrosine versus −0.29 °C with placebo during cooling (P < 0.05; no confidence interval reported) (Lang et al., 2020).

Low 🟩

Mood under prolonged stress or in depression ⚠️ Conflicted

Over an Antarctic winter, 12 g daily improved mood versus placebo (Palinkas et al., 2007). However, a randomized trial found no antidepressant effect in major depression (Gelenberg et al., 1990). Net: no reliable mood benefit outside unusual settings.

Magnitude: In winter, mood improved 47% with tyrosine versus a 136% worsening with placebo (P < 0.05 versus placebo; no confidence interval reported) (Palinkas et al., 2007).

Endurance exercise performance ⚠️ Conflicted

A meta-analysis of 8 placebo-controlled studies found no endurance effect (Solon-Júnior et al., 2023). Positive trials involved heat (Tumilty et al., 2011) or prior mental fatigue (Solon-Júnior et al., 2026); the heat result did not replicate (Tumilty et al., 2014). Net: no general endurance benefit.

Magnitude: Standardized mean difference (SMD, effect size in standard-deviation units; a standard deviation, SD, measures how widely individual values spread around the average) versus placebo was 0.02 for time to exhaustion and −0.04 for time trials, both non-significant (Solon-Júnior et al., 2023).

Blood pressure ⚠️ Conflicted

During combat training, cadets given 10 g tyrosine daily in protein-rich drinks had lower systolic blood pressure than those given carbohydrate drinks (Deijen et al., 1999); protein intake differed, making this indirect. A crossover trial in mild hypertension found no change (Sole et al., 1985). Net: no reliable effect.

Magnitude: Systolic blood pressure was lower than with the carbohydrate drink on day 6 of combat training (Deijen et al., 1999), while 7.5 g daily for 2 weeks left blood pressure unchanged in 13 adults with mild hypertension (Sole et al., 1985); neither published abstract reports a between-group outcome figure.

Attention-deficit symptoms in adults

In an open, uncontrolled 8-week trial in 12 adults with attention deficit disorder, most improved within 2 weeks but developed tolerance by week 6 (Reimherr et al., 1987). No placebo-controlled confirmation exists.

Magnitude: 8 of 12 participants showed a marked-to-moderate response at 2 weeks that was lost by 6 weeks (no control group) (Reimherr et al., 1987).

Neuropsychological outcomes in phenylketonuria ⚠️ Conflicted

Tyrosine becomes essential when phenylalanine cannot be converted to it. A Cochrane review of three randomized trials found higher blood tyrosine but no improvement in intelligence, neuropsychological performance, or growth (Remmington & Smith, 2021). Net: no demonstrated clinical benefit.

Magnitude: Blood tyrosine mean difference (average gap between groups) versus placebo was 23.46 (95% CI 12.87 to 34.05), with no significant difference in any clinical outcome (Remmington & Smith, 2021).

Speculative 🟨

Lifespan extension ⚠️ Conflicted

In fruit flies, tyrosine feeding extended lifespan (Parkhitko et al., 2020), yet tyrosine deprivation also did, though only at low total amino acid intake (Kosakamoto et al., 2024). The basis is animal-only and contradictory.

Benefit-Modifying Factors

  • Genetic polymorphisms: Carriers of the T/T form of the DRD2 C957T variant (DRD2 encodes the dopamine D2 receptor; T/T is thought to carry lower deep-brain dopamine) gained more in working-memory and stopping tasks than C/C carriers (Colzato et al., 2016).
  • Baseline performance and biomarkers: Low baseline performers improved while high performers worsened at letting new information into working memory (Jongkees, 2020); older adults start with higher baseline blood tyrosine and reach higher levels on the same dose (van de Rest et al., 2017).
  • Stress or task demand: Gains appear when stress or task difficulty degrades performance and are absent on easy tasks (Colzato et al., 2013; Thomas et al., 1999).
  • Sex: Trials enrolled mostly men (military studies) or only women (several Leiden studies), and none compared sexes directly, so sex-based differences in benefit are unknown.
  • Pre-existing conditions: No antidepressant effect was shown in major depression (Gelenberg et al., 1990), and only a mild, clinically insignificant effect in narcolepsy (a disorder of excessive daytime sleepiness) (Elwes et al., 1989); benefit seems limited to intact catecholamine systems (Jongkees et al., 2015).
  • Age: Older adults may gain cold-related temperature support (Lang et al., 2020) but showed working-memory decrements at doses above 100 mg/kg (van de Rest et al., 2017).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small, short trials, and no harm has been replicated across independent research groups.

Medium 🟥 🟥

Working-memory and response-control decrements in older adults at higher doses

In adults aged 60–75, 150 and 200 mg/kg produced worse high-load working-memory performance than 100 mg/kg, most clearly in those with the largest rises in blood tyrosine; older adults reached higher blood levels than young adults on the same dose (van de Rest et al., 2017). A placebo-controlled brain-imaging trial from the same Aarts group found tyrosine impaired anticipatory response slowing more with advancing age (Bloemendaal et al., 2018). The proposed mechanism is excess dopamine synthesis in an aging brain. Both trials were single-dose.

Magnitude: Hits on the hardest (3-back) level were 68.1% at 150 mg/kg (P = 0.041) and 66.6% at 200 mg/kg (P = 0.018) versus 75.2% at 100 mg/kg; the trial had no placebo arm and reported no confidence interval (van de Rest et al., 2017).

Thyroid hormone changes at high daily doses

Tyrosine is a building block of thyroid hormones. In a randomized placebo-controlled trial over an Antarctic winter, 12 g daily lowered thyroid-stimulating hormone (TSH, the pituitary signal that drives the thyroid) and raised free T3 (Palinkas et al., 2007). That dose is far above typical supplemental doses of 0.5–4 g, and the 4-week safety trial at those doses did not measure thyroid hormones (Matsumoto et al., 2026). Relevance is greatest for people with overactive thyroids or on thyroid medication.

Magnitude: In winter, TSH fell 28% with tyrosine and rose 18% with placebo (P < 0.05 versus placebo; no confidence interval reported) (Palinkas et al., 2007).

Heightened anger during severe psychological stress

In a randomized placebo-controlled trial of 78 military personnel undergoing mock interrogations, 300 mg/kg given before the stressor increased self-rated anger on the Profile of Mood States and changed no other mood, cortisol, or heart-rate measure (Lieberman et al., 2015). The authors suggest anger may be adaptive in captivity training; in everyday settings it may not be. This single trial has not been replicated.

Magnitude: Anger ratings rose more with tyrosine than placebo after the second interrogation and the next morning (treatment-by-session interaction, a test of whether the tyrosine effect differed across sessions, P = 0.002); the text reports no outcome figure, showing values only in a graph (Lieberman et al., 2015).

Low 🟥

Gastrointestinal upset ⚠️ Conflicted

Supplement references note digestive upset at higher doses (Examine). However, a 4-week randomized trial of 1–4 g daily found adverse events comparable to placebo, without a dose trend (Matsumoto et al., 2026). Net: generally well tolerated at common doses.

Magnitude: Adverse events of any type (none serious) numbered 4 at 4 g/day versus 4 on placebo, and 4, 5, and 1 at 1, 2, and 3 g/day, over 24 four-week periods per dose, with no dose trend (Matsumoto et al., 2026).

Higher blood tyrosine linked to type 2 diabetes ⚠️ Conflicted

Indirect: these studies concern the body’s own blood tyrosine, not supplements. Higher levels predicted type 2 diabetes in a cohort meta-analysis (Guasch-Ferré et al., 2016), but a genetic analysis suggested lower risk (Jäger et al., 2020), so the cohort link may reflect early disease rather than cause. Net: unresolved.

Magnitude: Risk ratio (risk relative to the comparison, here 36% higher) 1.36 (95% CI 1.19 to 1.55) for type 2 diabetes per SD higher blood tyrosine (Guasch-Ferré et al., 2016).

Higher blood tyrosine linked to shorter male lifespan

Indirect: this concerns the body’s own blood tyrosine, not supplements. In UK Biobank cohort and genetic analyses, higher tyrosine was linked to shorter lifespan, and after accounting for phenylalanine the genetic link held in men but not women (Zhao et al., 2025). No study has tested supplements against lifespan.

Magnitude: −0.91 years of life (95% CI −1.60 to −0.21) for genetically higher tyrosine in men, versus −0.36 years (95% CI −0.96 to 0.23, not significant) in women (Zhao et al., 2025).

Speculative 🟨

Melanoma promotion

Tyrosine is the precursor of melanin, so some labels caution people with a melanoma history (ConsumerLab). The basis is mechanistic only; no human data link supplementation to melanoma.

Migraine triggering

A drug reference notes tyrosine may trigger migraine (Drugs.com). The basis is mechanistic and anecdotal only, with no controlled data.

Risk-Modifying Factors

  • Genetic variants: Tyrosinemia and alkaptonuria (inherited defects in tyrosine-breakdown enzymes) cause tyrosine or its products to accumulate; DRD2 genotype changes how much cognitive benefit is gained (Colzato et al., 2016), but whether any variant raises harm is untested.
  • Baseline thyroid biomarkers: A low baseline TSH or high free T4 signals an overactive thyroid, where extra hormone precursor may add to excess hormone production (Palinkas et al., 2007).
  • Baseline blood tyrosine and metabolic health: Fatty liver disease raises blood tyrosine (Gobeil et al., 2022), so people with fatty liver already carry the elevated levels linked to diabetes risk.
  • Sex: The genetic lifespan association was significant in men but not women (Zhao et al., 2025); the 4-week safety trial enrolled only men (Matsumoto et al., 2026).
  • Pre-existing conditions: Hyperthyroidism or Graves’ disease (autoimmune overactive thyroid), migraine, and use of monoamine oxidase inhibitors (an older antidepressant class) (Drugs.com), plus melanoma history (ConsumerLab), raise risk; levodopa’s effect in Parkinson’s disease may be blunted (theoretical; Nutt et al., 1984).
  • Age: Older adults reach higher blood tyrosine on the same weight-based dose and showed dose-related cognitive decrements above 100 mg/kg (van de Rest et al., 2017).

Key Interactions & Contraindications

Prescription drugs:

  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, isocarboxazid, selegiline): Avoid (theoretical). Listed as contraindicated because tyrosine-derived amines could accumulate and sharply raise blood pressure (Drugs.com); one intravenous-nutrition case with selegiline showed no reaction (Bharani et al., 2024).
  • Levodopa (carbidopa-levodopa): Caution (theoretical for tyrosine). Other large neutral amino acids reversed levodopa’s effect by competing for brain transport (Nutt et al., 1984); tyrosine uses that carrier, risking poorer Parkinson’s symptom control. Separating doses by several hours is the usual mitigation.
  • Thyroid medications (levothyroxine, liothyronine, methimazole): Caution (theoretical). High-dose tyrosine lowered TSH in a placebo-controlled trial (Palinkas et al., 2007), which could shift replacement needs or work against antithyroid treatment. TSH monitoring after starting is the usual mitigation.
  • Stimulants and catecholamine-raising antidepressants (methylphenidate, amphetamine salts, bupropion): Monitor (theoretical). Additive dopamine and noradrenaline effects could raise heart rate, blood pressure, or agitation; Examine rates interaction potential with bupropion-type drugs as low (Examine FAQ). Starting low with blood-pressure and heart-rate checks mitigates this.

Over-the-counter medications:

  • Decongestants (pseudoephedrine, phenylephrine): Monitor (theoretical). Both stimulate the adrenaline system that tyrosine feeds, so combined use could add to blood-pressure and heart-rate rises. Spacing doses apart and checking blood pressure mitigate this.
  • Caffeine-containing products (caffeine tablets, energy drinks, pre-workout powders): Monitor (theoretical). Effects on alertness and heart rate may add up; no published trial of the combination was found, and a planned trial will compare them (NCT07530185). Limiting caffeine on dosing days mitigates this.

Supplements:

  • Competing amino acids (branched-chain amino acids such as leucine, isoleucine, valine; tryptophan; phenylalanine): Caution (theoretical). They compete for the same brain transporter, reducing tyrosine entry (Fernstrom & Fernstrom, 2007). Spacing tyrosine apart from amino acid blends and protein shakes avoids this.
  • Additive dopamine or adrenaline-system supplements (Mucuna pruriens, which contains L-DOPA; phenylethylamine; yohimbine; synephrine): Monitor (theoretical). Stacking may overshoot catecholamine signaling, causing restlessness, raised blood pressure, or rebound fatigue. Adding one agent at a time limits this.
  • Iodine or thyroid glandular supplements: Caution (theoretical). Extra thyroid-hormone raw materials could add to thyroid stimulation in susceptible people, risking overactive-thyroid symptoms. TSH monitoring detects this.

Other interventions:

  • Protein-rich meals: Monitor (reduced effect). Meal protein supplies competing amino acids, yet tyrosine taken before protein-containing meals still raised the plasma tyrosine ratio governing brain entry from 0.13 to 0.21 (Melamed et al., 1980). Dosing apart from meals maximizes uptake.

Populations who should avoid L-Tyrosine:

  • People taking monoamine oxidase inhibitors (Drugs.com)
  • People with hyperthyroidism or Graves’ disease (Drugs.com)
  • People with tyrosinemia or alkaptonuria, inherited disorders of tyrosine breakdown
  • People with a history of malignant melanoma, per supplement label warnings (ConsumerLab)
  • Pregnant or breastfeeding women, for whom safety data are lacking (Drugs.com)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Thyroid screening first: A TSH check before regular use, with tyrosine avoided if TSH is below the laboratory range, mitigates worsening of an overactive thyroid and the TSH shifts seen at high doses (Palinkas et al., 2007).
  • Dose cap after 60: Keeping doses at or below 100 mg/kg mitigates the dose-related working-memory decrements seen at 150–200 mg/kg in older adults (van de Rest et al., 2017).
  • Situational rather than continuous use: Reserving tyrosine for predictable high-demand days limits the chronically elevated blood tyrosine that observational and genetic studies associate with diabetes risk (Guasch-Ferré et al., 2016) and shorter male lifespan (Zhao et al., 2025).
  • Split large doses: Dividing large doses into two portions taken 30 minutes apart reduces the risk of digestive upset (Examine).
  • Separation from levodopa: Spacing tyrosine several hours apart from levodopa avoids levodopa reducing tyrosine absorption (ConsumerLab) and amino acid competition for brain transport that could blunt Parkinson’s symptom control (Nutt et al., 1984).
  • No combination with monoamine oxidase inhibitors: Avoiding this pairing entirely prevents a theoretical hypertensive crisis (dangerous blood-pressure spike).
  • Tracking irritability and headaches: Stopping when anger, irritability, or migraine-type headaches appear within hours of dosing limits the mood and headache risks described above (Lieberman et al., 2015).

Therapeutic Protocol

Parameters without a citation (timing, splitting, titration) reflect common practice.

  • Acute weight-based dose (military protocol): 100–150 mg/kg about 1–2 hours before the stressor, as used by Army and Navy researchers (Banderet & Lieberman, 1989; Shurtleff et al., 1994; Thomas et al., 1999).
  • Acute fixed dose (cognitive-control protocol): 2 g in juice about 60 minutes before demanding mental work, the Leiden group’s protocol (Colzato et al., 2013; Steenbergen et al., 2015).
  • Higher split dose: Two 150 mg/kg doses (300 mg/kg total) before successive stressors (Mahoney et al., 2007); a single 150 mg/kg dose raised serum tyrosine as effectively as a double dose (Coull et al., 2016).
  • Daily low-dose approach (manufacturer protocol): Manufacturers commonly recommend 500–1,500 mg daily, and more than 12 g daily is discouraged (Drugs.com); 1–4 g daily for 4 weeks was tolerated (Matsumoto et al., 2026).
  • Food-first approach (dietary protocol): About 2 g of tyrosine comes from roughly 2.4–3.3 three-ounce servings of chicken, beef, pork, or salmon (ConsumerLab), although meals also supply competing amino acids.
  • Practitioner use: Andrew Huberman presents L-Tyrosine as a dopamine-precursor focus aid, citing 500–1,000 mg in capsule or powder form, in his widely followed dopamine episode (Huberman Lab).
  • Time of day: Morning or shortly before the planned demand. Given after 36 hours awake, it did not alter recovery sleep (Waters et al., 2003), but late-evening doses are avoided in common practice.
  • Half-life and duration: In four adolescents, blood tyrosine peaked about 2–3 hours after a dose and neared baseline by 8 hours (Hart et al., 2021); performance effects during sleep loss lasted about 3 hours (Neri et al., 1995).
  • Single versus split doses: A single dose suits acute use; large doses can be split 30 minutes apart for digestive comfort (Examine), and daily regimens were divided across three meals (Matsumoto et al., 2026).
  • Genetic polymorphisms: DRD2 T/T carriers responded more (Colzato et al., 2016); COMT (catechol-O-methyltransferase, the enzyme that clears prefrontal dopamine) variants are a theoretical modifier without tyrosine dose data.
  • Sex differences: No sex-specific dosing data exist; weight-based dosing adjusts for body size, and multi-week tolerance data come only from men (Matsumoto et al., 2026).
  • Age: After 60, 100 mg/kg outperformed 150–200 mg/kg on hard working-memory tasks (van de Rest et al., 2017), while 150 mg/kg aided cold tolerance (Lang et al., 2020).
  • Baseline biomarkers: Older adults had higher baseline blood tyrosine, and larger rises after dosing predicted larger working-memory decrements (van de Rest et al., 2017); common practice checks baseline TSH before regular use.
  • Pre-existing conditions: Thyroid disease, Parkinson’s disease on levodopa, melanoma history, and migraine are the conditions where avoidance or physician supervision is common practice (see Key Interactions & Contraindications).

Discontinuation & Cycling

  • Short-term or situational: Evidence supports acute use before specific stressors; no data support lifelong daily use.
  • Withdrawal effects: None reported; blood tyrosine returned to baseline during 2-week washouts between 4-week dosing periods (Matsumoto et al., 2026).
  • Tapering: Not required, given the absence of withdrawal effects; trials stopped dosing abruptly.
  • Cycling and tolerance: Benefits in an open attention-deficit trial faded by week 6 (Reimherr et al., 1987), suggesting intermittent use may preserve effects; no controlled cycling studies exist.

Sourcing and Quality

  • Form: Trials used free-form L-Tyrosine powder (Colzato et al., 2013; van de Rest et al., 2017). N-acetyl-L-tyrosine is marketed as better absorbed, but whether it works better is unclear (Examine).
  • D- and DL-forms: D-Tyrosine depressed growth in mice, so reputable supplements contain only the L-form (ConsumerLab).
  • Purity standard: The US Food and Drug Administration (FDA) applies Food Chemicals Codex specifications to food-grade L-Tyrosine in the Code of Federal Regulations (CFR) (21 CFR 172.320); trial material exceeded 99% purity (Matsumoto et al., 2026).
  • Third-party testing: Independent certification (NSF International, United States Pharmacopeia, or Informed Choice) verifies content and contaminants; ConsumerLab has published an evidence summary on tyrosine, not a product test.
  • Brands and suppliers: Trials used Bulkpowders powder (Colzato et al., 2013) and Ajinomoto amino acid (Matsumoto et al., 2026); widely sold brands include NOW Foods, Thorne, and Life Extension.
  • Powder for weight-based dosing: Weight-based protocols require large amounts, about 21 g for a 70-kg adult at 300 mg/kg (Lieberman et al., 2015), which is impractical with small capsules.

Practical Considerations

  • Time to effect: Acute effects are timed to peak blood levels about 1–2 hours after dosing (Colzato et al., 2013); the only multi-month trial assessed mood at the end of an Antarctic winter of daily dosing (Palinkas et al., 2007).
  • Common pitfalls: Taking it with a protein-rich meal, expecting a boost when rested and unstressed, using high weight-based doses after 60, and stacking it with several stimulants.
  • Regulatory status (US): L-Tyrosine is a permitted food additive under FDA regulation, listed among the amino acids that may be added to foods as nutrients (21 CFR 172.320).
  • Regulatory status (European Union, EU): The European Commission refused the claim “L-tyrosine is essential for the natural formation of dopamine” because no effective intake could be specified (Regulation (EU) No 155/2014).
  • Cost and access: Inexpensive and sold without prescription; cost and access are not meaningful barriers.
  • Who was studied: Most data come from young, healthy, often military volunteers in single laboratory sessions, which limits how well results transfer to older adults’ daily lives.

Interaction with Foundational Habits

  • Sleep: Indirect. Tyrosine blunted the performance decline of a sleepless night (Neri et al., 1995) and did not change recovery sleep (Waters et al., 2003). It does not replace sleep, and earlier-day dosing avoids stimulation at bedtime.
  • Nutrition: Direct. Habitual protein supplies about 2.8–3.5 g of tyrosine daily (Matsumoto et al., 2026). Protein-rich meals add competing amino acids that limit brain uptake (Fernstrom & Fernstrom, 2007), so supplements are usually taken apart from meals.
  • Exercise: None for endurance (Solon-Júnior et al., 2023); possibly potentiating when exercise follows mental fatigue (Solon-Júnior et al., 2026). It supported core temperature in older adults during cold (Lang et al., 2020). Trials dosed about 60 minutes before sessions.
  • Stress management: Indirect. Tyrosine did not lower cortisol, heart rate, or salivary stress markers during severe or simulated stress (Lieberman et al., 2015; McAllister et al., 2024), and it increased anger in one trial; it may protect performance without reducing the stress response.

Monitoring Protocol & Defining Success

Baseline testing: before regular or high-dose use, common practice is a thyroid panel (TSH and free T4) plus a review of thyroid disease, melanoma history, and interacting medications. A baseline plasma amino acid panel is optional but lets later values be judged against the individual’s own level. For occasional acute use at standard doses, common practice limits baseline testing to the thyroid panel.

Ongoing monitoring: for daily use, TSH and free T4 are typically repeated at 4–8 weeks, then every 6–12 months; occasional users are typically retested only if symptoms arise. Home blood-pressure checks during the first week help those combining tyrosine with other stimulating compounds. Success means noticeably better performance on demanding days, judged against comparable days without tyrosine, without irritability, headaches, digestive upset, or thyroid changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Thyroid-stimulating hormone (TSH) 0.4–4.0 mIU/L (standard reference range) Safety check: a falling value stops or changes use High-dose tyrosine lowered TSH (Palinkas et al., 2007); morning draw; best paired with free T4; no fasting needed
Free thyroxine (free T4) 0.8–1.8 ng/dL (standard reference range) Safety check: a rising value stops use Paired with TSH to detect thyroid overstimulation; biotin supplements are usually paused 48 hours before testing to avoid assay interference
Plasma tyrosine (plasma amino acid panel) 34–112 µmol/L (standard reference range); track change from own baseline Expected to change: confirms intake and absorption Fasting levels were 1.23-fold higher than placebo at 4 g/day, from a baseline of about 61 µmol/L (Matsumoto et al., 2026); fasting draw; time since last dose strongly affects results

Qualitative markers:

  • Focus under load: clarity and error rate during demanding tasks, compared with similar days without tyrosine
  • Mood and irritability: any rise in anger or irritability under stress
  • Headaches: new or migraine-type headaches after dosing
  • Digestive comfort: nausea or gastrointestinal discomfort
  • Sleep onset: time to fall asleep on dosing days
  • Heart rate and palpitations: especially when combined with caffeine

Emerging Research

  • Perioperative anxiety trial (SPOT, NCT05782829): Placebo-controlled trial of L-Tyrosine for anxiety around outpatient surgery (150 participants, Nice University Hospital); registered completion (May 2026) has passed, yet it is listed as recruiting, without results. A positive result would extend stress benefits to clinical anxiety; a null result would confine them to laboratory stressors.
  • Elite boxers trial (NCT07530185): Planned (not yet recruiting) crossover trial (18 boxers, completion March 2027) of L-Tyrosine, caffeine, and both combined on Stroop (color-word attention) performance. A positive result would support cognitive benefit under sport stress; a null result would weaken it outside laboratory stressors.
  • Military recovery trials (NCT04549194; NCT04518254): French armed-forces trials of 1-month L-Tyrosine after deployment (burnout scores, 116 participants) and of decision-making under stress (17 participants) completed in 2021 and 2022; no results are posted or published.
  • Tyrosine and glucose tolerance (NCT03872557): Columbia University study of whether oral tyrosine changes glucose tolerance and insulin secretion, completed January 2020 with no results posted; findings would bear directly on the diabetes-risk question.
  • Lifespan genetics: A 2025 cohort and genetic analysis linked higher tyrosine to shorter male lifespan (Zhao et al., 2025), while a 2020 genetic analysis suggested lower diabetes risk (Jäger et al., 2020); replication in other cohorts could strengthen or weaken the longevity concern.
  • Animal longevity models: Fruit-fly studies disagree: tyrosine feeding extended lifespan (Parkhitko et al., 2020) and tyrosine deprivation also did (Kosakamoto et al., 2024); mammalian studies could clarify which direction applies.
  • Dose-finding in aging: Placebo-controlled trials below 100 mg/kg in older adults (van de Rest et al., 2017) and genotype-guided studies (Colzato et al., 2016) could show whether lower doses help or harm aging brains.
  • Dietary tyrosine and cognition: In 1,724 Berlin Aging Study II participants, higher habitual tyrosine intake was associated with better working memory, fluid intelligence, and episodic memory (Kühn et al., 2019); intervention trials could test whether this is causal.
  • Long-term safety: The only multi-week safety trial lasted 4 weeks, enrolled only men, and was manufacturer-funded (Matsumoto et al., 2026); longer independent trials including women could strengthen or weaken the case for daily use.

Conclusion

L-Tyrosine is a common dietary amino acid that the brain turns into dopamine and related chemical messengers. As a supplement, its best-supported use is narrow: a single dose taken before a demanding or stressful situation appears to help protect short-term memory and attention when cold, low oxygen, sleep loss, or heavy mental demand is dragging performance down. Even there, several trials found little or no effect, and the gains are small and limited to particular tasks. The evidence does not show reliable benefits for endurance, blood pressure, everyday mood, depression, or inherited metabolic disease.

For health-focused adults, the more important questions concern aging and long-term use. In older adults, higher doses were linked to worse performance on hard memory tasks, although one small study found help with keeping the body warm in the cold. Very high daily intake shifted thyroid signals, and studies of people’s own blood tyrosine, rather than supplements, tie higher levels to diabetes risk and, in men, a shorter lifespan, while other genetic findings point the opposite way. Short-term use at common doses has been well tolerated.

The evidence base is thin: mostly small, brief laboratory studies, much of it from military research programs, and the main multi-week safety trial was run by an amino acid manufacturer, a financial conflict of interest. Overall, L-Tyrosine looks like a low-cost, situational tool with modest and uncertain thinking benefits and open questions about daily use, rather than a proven longevity intervention.

Top - Benefits - Risks - Protocol